JPMorgan analyst Rachel Vatnsdal raised the firm’s price target on Adaptive Biotechnologies (ADPT) to $20 from $17 and keeps an Overweight rating on the shares following the Q3 report.
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge-fund level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ADPT:
- Adaptive Biotechnologies: Strong Q3 Performance and Favorable Conditions Drive Buy Rating
- Adaptive Biotechnologies Reports Strong Q3 2025 Growth
- Strong Q3 Performance and Market Position Drive Buy Rating for Adaptive Biotechnologies
- Adaptive Biotechnologies reports Q3 EPS 6c, consensus (14c)
- AMD, PLTR, NFLX: Cathie Wood Loads Up on HOOD and Netflix, Sells Advanced Micro and Palantir Stocks